BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.
Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)
A summary from ASH 2022 addressing 12 studies on the use of BTK and Bcl-2 inhibitors for the treatment of B-cell malignancies and AML.
Slide kit describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Poster presented at ASH 2022 evaluating a new therapeutic approach for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.